Proto Axiom
Venture studioNorth Sydney · Pre-Seed–Seed · 28 people tracked
Investment thesis
Proto Axiom operates as a company creator and holding company rather than a conventional venture fund, building enterprises from breakthrough Australian science. It combines scientific diligence, capital deployment and hands-on company building, deploying a shared operating bench of clinical, regulatory, IP, finance and governance experts across its portfolio. The same specialists who handle IP licensing, IND filings and Series A financial modeling rotate across portfolio companies as their programs advance through preclinical and clinical gates. The focus is on drug development, translation and life sciences, with an emphasis on guiding programs from research through clinical milestones. The team, not capital alone, is presented as the core product.
Source: firm website, verified Aug 3, 2026.
Team · 28 people
from the firm's websiteFounding CEO of Proto Axiom, building it into a company-creation platform focused on Australian science. Previously co-founded Applecart, a New York data and technology company that received a US$100M investment from Blackstone Growth.
Operating Partner focused on operations.
Chair of Strategic Advisors with experience at Pfizer and Novo Nordisk.
Non-Executive Director, former CEO of Dimension Therapeutics and former Head of Global Drug Development at Merck Serono, contributing to development of over 30 therapeutics.
Chair of the Scientific Advisory Board with over 30 years in vaccines and gene therapy.
Chief of Staff focused on strategy.
Board chairman with over 20 years as a lawyer, including a decade in Asia. Named an Innovative Leader in the 2020 FT Innovative Lawyers Awards Asia Pacific.
Chief Operating Officer with a legal and risk background.
Strategic Advisor and former CFO of GSK and HSBC.
Scientific Advisor with experience at Novartis and Spica Therapeutics.
Head of Finance with finance and pharma operations experience.
Non-Executive Director with two decades in life-sciences business development and investment at Johnson & Johnson and Sanofi, deploying over US$1B across ANZ in licensing and acquisitions.
Investment Associate with a PhD.
Strategic Advisor and CIO of Scientia Capital.
Chief Science Officer focused on drug development and translation.
Business Manager.
Scientific Advisor with experience at LEO Pharma and GlaxoSmithKline.
Strategic Advisor associated with AusBiotech and PBAC.
Entrepreneur in Residence with a founder-operator background in nanomedicine.
Non-Executive Director who spent 20 years as CEO of Uniseed, the A$200M partnership between Australian research institutions and UniSuper, and led multiple biotech exits.
Science Analyst with a PhD.
Strategic Advisor specializing in IP advisory, associated with Spruson & Ferguson.
Scientific Advisor with experience at CSL Ltd and Starpharma.
Non-Executive Director and Senior Advisor at Catalio Capital Management, with over 25 years across medicine, equity capital markets and life-sciences investment management.
Scientific Advisor associated with the Saudi Ministry of Investment.
Non-Executive Director and Managing Director of Dragoman. Former President of Corporate Development at BHP and former Non-Executive Chairman of Dow Chemical Australia.
Non-Executive Director, co-founder and first CEO of Boston-based Life Biosciences, with 18 years in global funds management at Goldman Sachs Asset Management and Brevan Howard.
Scientific Advisor affiliated with UMass Medical and Harvard Medical.
Investments · 5 tracked
founders shown can be your intro pathLater-stage radiopharmaceutical company; Proto Axiom holds strategic exposure alongside its company-creation core; Phase 2 212Pb-ADVC001 readout expected late 2026.
NAD+ platform with IVF media as lead application (UNSW/UQ); founding investor, re-domiciled to Australia from the US; clinical stage with sibling-embryo trials and FDA 510(k) progress.
Therapeutics company formed from Australian translational science, with a topical antifungal lead in Phase IIb; supported by Proto Axiom's operating bench.
Platform opportunity sourced from UNSW; Proto Axiom co-creator focused on platform commercialisation strategy and team building.
Frequently asked questions
- What stage does Proto Axiom invest at?
- Proto Axiom invests at the Pre-Seed, Seed stages.
- What sectors does Proto Axiom focus on?
- Proto Axiom focuses on Biotech, Deep Tech, Healthtech, Medical Devices.
- Where is Proto Axiom located?
- Proto Axiom is headquartered in North Sydney, AU.
- Does Proto Axiom lead rounds?
- Yes, Proto Axiom leads investment rounds.
Similar investors
Amadeus Capital Partners is a technology investor. It held a first close of $75M on its Amadeus IV Digital Prosperity Fund, focused on late-stage venture and growth companies building online and mobile services for emerging-market middle classes.
DCVC (Data Collective) is a deep tech venture capital firm backing entrepreneurs using computational approaches to solve large real-world problems across many industries. It operates six flagship funds plus DCVC Bio, spanning 13 funds to date.
Innovestor is a Finland-based investment group active in venture capital, life science and health, technology, real estate, and energy storage, also offering angel co-investment and corporate venturing services.
Khosla Ventures is a venture capital firm known for backing bold, contrarian bets in world-class teams that can reshape entire industries.
Pacific Channel is an Asia-Pacific funds management firm specialising in deep-tech venture capital and alternative investments, focused on agriculture/food, health and the environment.